PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29387014-0	2018	Inhibiting beta-Catenin by beta-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy.	norharman	27-41	catenin beta 1	Homo sapiens	11-23	
29387014-5	2018	In the present study, we utilized SP141 as an exemplary beta-carboline compound to characterize beta-catenin as a molecular target of the beta-carboline compounds and to demonstrate an important role of beta-catenin in the anticancer activity of beta-carboline.	norharman	138-152	catenin beta 1	Homo sapiens	96-108	
29387014-5	2018	In the present study, we utilized SP141 as an exemplary beta-carboline compound to characterize beta-catenin as a molecular target of the beta-carboline compounds and to demonstrate an important role of beta-catenin in the anticancer activity of beta-carboline.	norharman	138-152	catenin beta 1	Homo sapiens	96-108	
29387014-10	2018	We envision that beta-carboline derivatives can be developed as promising dual inhibitors of beta-catenin and MDM2 for the treatment of advanced pancreatic cancer.	norharman	17-31	catenin beta 1	Homo sapiens	93-105